Working... Menu
Trial record 1 of 1 for:    16226444 [PUBMED-IDS]
Previous Study | Return to List | Next Study

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (AKTIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01466868
Recruitment Status : Terminated (Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions)
First Posted : November 8, 2011
Last Update Posted : July 10, 2014
National Cancer Institute, France
Information provided by (Responsible Party):
Centre Leon Berard

Brief Summary:
The purpose of this study is to evaluate the antitumor efficacy and the safety of MK 2206 in patients with relapsed or refractory diffuse large B cell lymphoma.

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Drug: MK2206 Phase 2

Detailed Description:

Diffuse Large B-cell Lymphoma (DLBCL) is the most frequent subtype of Non-Hodgkin lymphoma (NHL) around the world, in all age groups.

DLBCL is a curable disease and combination of monoclonal antibody against CD20 (rituximab) with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen have improved the prognosis of patients with a 20% increase of the cure rate. For the remaining patients who are not in complete response and/or who relapse after first line therapy, the possibility of cure is dramatically reduced.

As PI3K/AKT/mTOR pathway regulates the expression of cyclin D1, c-Myc and Stat3 proteins, which are involved in the pathogenesis of DLBCL HL), this signalling axis is an emerging therapeutic target for treatment of DLBCL.

One study has shown that the level of p-Akt is an adverse prognostic feature in DLBCL and is found in 52% of tumors samples from DLBCL patients.

Given the fact that AKT is overactivated in about to 52% of DLBCL and is considered as a poor prognosis factor, we postulate that targeting AKT in DLBCL may be an interesting therapeutic strategy.

MK-2206 is an orally selective allosteric inhibitor of AKT developed by MERCK currently highlighted as a promising therapeutic option for cancer patients and under clinical development in several Phase 1 trials.

Therefore, we propose to conduct a Phase II study using a two-stage Simon's design with objective response rate (ORR) as the primary endpoint.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Study Start Date : November 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: MK2206
Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
Drug: MK2206

Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.

The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms.

Primary Outcome Measures :
  1. evaluation of the antitumor activity of MK-2206 in terms of objective response rate (ORR). [ Time Frame: 4 months after the first day of treatment. ]
    the objective response rate (ORR) is measured as per 2007 Cheson international response criteria.

Secondary Outcome Measures :
  1. safety profile [ Time Frame: during the treatment and up to 3.5 years from the first inclusion ]
    safety profile is characterized by type, frequency and seriousness of the toxicities showed by patients and graded using CTCAE-V04.

  2. overall survival [ Time Frame: from the date of inclusion to the date of death from any cause (up to 3.5 years from the first inclusion) ]
  3. progression-free survival [ Time Frame: from the date of inclusion to the date of event defined as the first documented disease progression or death from any cause (up to 3.5 years from the first inclusion) ]
  4. duration of response [ Time Frame: from the time of first documented response (complete response or partial response) until the first documented disease progression or death due to underlying cancer (up to 3.5 years from the first inclusion) ]
  5. evaluation of the antitumor activity of MK-2206 in terms of objective response rate (ORR). [ Time Frame: 4 months after the first day of treatment ]
    the objective response rate (ORR) is measured as per 1999 Cheson international response criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically confirmed diffuse large B-Cell lymphomas.
  • Patients must have measurable disease.
  • Subjects must have received at least two prior treatment lines.There is no maximal limit on the number of prior therapies

    • Prior treatment must include CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) -like chemotherapy in combination with rituximab. Rituximab used alone is not considered as a separate regimen.
    • Prior treatment could include high dose chemotherapy with autologous stem-cell transplantation if patients had progressed ≥ 3 months after this treatment.
    • Salvage treatment, mobilization chemotherapy, high-dose chemotherapy and planned post-transplant therapy should be considered as one regimen
    • Relapsed or refractory patients who are candidate to high-dose chemotherapy and autologous or allogenic stem cell transplantation are not eligible.
  • Patients must have discontinued all prior therapies for at least 5 times the t1/2 of prior anti-cancer therapies before study entry.
  • Male or female patients, age ≥ 18 years.
  • Life expectancy greater than 4 months.
  • ECOG performance status ≤2.
  • Patients must have normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1.5 x 109/L,
    • Platelet count ≥ 100 x 109/L or ≥75 x 109/L if the bone marrow is involved,
    • AST/ALT ≤ 2.5 x upper limit of normal (ULN) (or ≤ 5.0 x ULN if liver metastasis) direct bilirubin ≤ 1.5ULN
    • Calculated creatinine clearance (Cockcroft-Gault formula) of ≥ 50mL/min
  • Patients must agree to use adequate double contraception
  • Patients must be able to swallow whole tablets.
  • Cardiovascular baseline QTcF≤ 450 msec (male) or QTcF≤470msec (female).
  • Signed written informed consent document.
  • Patients with French Social Security in compliance with the French law relating to biomedical research.

Exclusion Criteria:

  • Tumor tissue sample not available for pathological review.
  • Patients with others than Diffuse large B-Cell Lymphoma histology.
  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
  • Patients who have not recovered from adverse events grade > 1 due to agents administered more than 4 weeks earlier.
  • Patients who are receiving any other investigational agents.
  • Patients with known CNS involvement should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the compliance to the study protocol.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 tablets.
  • Patients with uncontrolled hyperglycemia
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and breastfeeding women are excluded from this study.
  • HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MK-2206.
  • Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption.
  • Patients with clinically important history of liver disease, including viral or other hepatitis or cirrhosis.
  • Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years.
  • Uncontrolled hypertension with resting SBP>140 or resting DBP>90mm Hg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01466868

Layout table for location information
Institut Bergonié
Bordeaux, France, 33000
Centre Henri Mondor
Créteil, France
Lille, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France, 13000
CHU St Eloi
Montpellier, France
Nancy, France
CHU de Nantes
Nantes, France
Hôpital Saint-Louis
Paris, France, 75010
Hôpital Necker
Paris, France, 75014
Centre Hospitalier LYON SUD
Pierre Bénite, France
Centre Henri Becquerel
Rouen, France
Institut Gustave Roussy
Villejuif, France
Sponsors and Collaborators
Centre Leon Berard
National Cancer Institute, France
Layout table for investigator information
Principal Investigator: Hervé Ghesquières, MD Centre Leon Berard, Lyon, France
Principal Investigator: Philippe Cassier, MD Centre Leon Berard

Reeder CB, Gornet MK, Habermann TM, et al.: A phase II trial of the oral mTOR inhibitor Everolimus (RAD001) in relapsed aggressive Non-Hodgkin Lymphoma (NHL), in (ed 110; Abstract 121), 2007
Johnson PB, Ansell SM, Colgan JP, et al.: Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma, in (ed 25, No. 18S, Abstract 8055), 2007

Layout table for additonal information
Responsible Party: Centre Leon Berard Identifier: NCT01466868     History of Changes
Other Study ID Numbers: AKTIL
First Posted: November 8, 2011    Key Record Dates
Last Update Posted: July 10, 2014
Last Verified: July 2014

Keywords provided by Centre Leon Berard:
Diffuse Large B cell Lymphoma
MK 2206
objective response rate
progression free survival
overall survival

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin